Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

Related Articles

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

6 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

5 months ago

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

3 months ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

6 months ago

Category

You may also like

Stock News•15 hours ago

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

Eli Lilly (LLY) holds bullish Wall Street analyst ratings, with media reports on rating changes potentially influencing its stock price. Investors weigh sell-side recommendations when deciding on LLY ...

LLY

Share

Stock News•1 week ago

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb faces Eliquis patent expiry in 2028, a key revenue risk. The company is advancing new drugs and pipeline candidates to offset projected losses, though near-term financial impact r...

BMY

Share

News•2 weeks ago

Emily Field: Large pharma companies are going to continue looking at biotech

Biotech is gaining momentum as M&A returns, capital markets reopen, and cancer vaccine breakthroughs fuel investor interest, per Barclays' Emily Field. Large pharma companies are expected to continue ...

Share